Home NMPA Approves Registration of 187 Medical Devices in September 2023

NMPA Approves Registration of 187 Medical Devices in September 2023

Oct 26, 2023 14:43 CST Updated 14:43
Hanyu Medical

Structural Heart Disease Interventional Devices and Electrophysiology Product R&D, Manufacturer

Introduction: Latest release by the National Medical Products Administration!

On October 26, the National Medical Products Administration (NMPA) released the "Announcement of the National Medical Products Administration on the Approval and Registration of 187 Medical Device Products (September 2023) (No. 136 of 2023)."


640.png

Source of the image: NMPA official website


According to the announcement, in September 2023, the National Medical Products Administration (NMPA) approved the registration of 187 medical device products. This includes 137 Class III medical devices produced in China, 25 imported Class III medical devices, 24 imported Class II medical devices, and 1 medical device product from Hong Kong, Macao, or Taiwan (specific products are listed at the end).

Among them, Hanyu Medical's Mitral Valve Clip System is an innovative medical device, and it is also the first domestically produced mitral regurgitation interventional device approved for marketing in China.

According to statistics, from January to September this year, the National Medical Products Administration has approved the registration of 1,867 medical device products.

Table 1 Catalog of Medical Device Products Approved for Registration in September 2023

1.png

2.png

3.png

4.png

5.png

6.png

7.png

8.png

9.png

89.png

456.png

Source: NMPA official website


894ba01ed5dfb2d99b6ca51913f1e28.png


Editor: Penicillin


Disclaimer: The views expressed in this article are solely those of the author and do not represent the position of PharmCube. We welcome exchanges and additional input in the comment section; for reprints, please be sure to credit the author and source. If there are any issues regarding the content, copyright, or other aspects of the work, please leave a message on this platform, and we will address it promptly.